Antagonist Treatment for Opioid Dependence: Promise and Hurdles

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Treatment Options in Psychiatry

• Publication date

  2017-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40501-017-0110-4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

  2016cited by this paper
• Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant

  2016cited by this paper
• Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]

  2016cited by this paper
• Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.

  2015cited by this paper
• A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.

  2015cited by this paper
• Studies of EN-1639A (naltrexone): a new narcotic antagonist.

  2015cited by this paper
• [Stabilization of remission in patients with opioid dependence with naltrexone implant: a pharmacogenetic approach].

  2015cited by this paper
• Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.

  2013cited by this paper
• Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.

  2013cited by this paper
• Multivariate Analysis of Dopaminergic Gene Variants as Risk Factors of Heroin Dependence

  2013cited by this paper
• Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis

  2012cited by this paper
• Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.

  2012cited by this paper
• Injectable extended-release naltrexone for opioid dependence.

  2011cited by this paper
• Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

  2011cited by this paper
• Oral naltrexone maintenance treatment for opioid dependence.

  2011cited by this paper
• Genetic, personality, and environmental predictors of drug use in adolescents.

  2010cited by this paper
• A stress-coping profile of opioid dependent individuals entering naltrexone treatment: a comparison with healthy controls.

  2009cited by this paper
• Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial

  2009cited by this paper
• Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

  2009cited by this paper
• Pharmacologic treatments for opioid dependence: detoxification and maintenance options

  2007cited by this paper
• Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment.

  2007cited by this paper
• Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings

  2007cited by this paper
• Naltrexone for probationers and parolees.

  2006cited by this paper
• Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.

  2006cited by this paper
• Increased Attributable Risk Related to a Functional μ-Opioid Receptor Gene Polymorphism in Association with Alcohol Dependence in Central Sweden

  2005cited by this paper
• Naltrexone for heroin dependence treatment in St. Petersburg, Russia.

  2004cited by this paper
• Clinical evaluation of a naltrexone sustained-release preparation.

  1985cited by this paper
• Nontolerance to the opioid antagonism of naltrexone.

  1985cited by this paper

• Use of nalmefene and behavioral counseling in patients with combined opioid and alcohol dependence

  2025cites this paper
• Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation

  2020cites this paper
• Types of Medication-Assisted Treatment for Opioid Use Disorder in Turkey: The Perceptions of Inpatients about Treatment Success

  2020cites this paper